03/16/2026 | Press release | Distributed by Public on 03/16/2026 14:41
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Departure of Director
On March 13, 2026, Zachary Prensky notified the Board of Directors (the "Board") of LB Pharmaceuticals Inc (the "Company") of his intent to retire as a member of the Board and therefore not stand for reelection at the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting"). Accordingly, Mr. Prensky's term as a director will end when his current term expires at the 2026 Annual Meeting. Mr. Prensky will remain as a member of the Board and as a member of the Nominating and Corporate Governance Committee of the Board until the conclusion of the 2026 Annual Meeting.
Mr. Prensky's decision to resign was not a result of any disagreement with the Company on any matter related to the Company's operations, policies or practices. Following his resignation date, Mr. Prensky is expected to provide consulting services to the Company. The Board thanks Mr. Prensky for his years of service and valuable contributions to the Company.
In connection with Mr. Prensky's separation from the Company, the Company and Mr. Prensky entered into an Amendment No. 1 to Transition, Separation, and Consulting Agreement (the "Transition Agreement Amendment"), effective June 3, 2026, which amended that certain Transition, Separation, and Consulting Agreement, dated November 26, 2024 (the "Transition Agreement"). Pursuant to the Transition Agreement Amendment, Mr. Prensky will continue to provide consulting services as may be reasonably requested by the Company and receive the benefits described in the Transition Agreement. In addition, Mr. Prensky's outstanding and unvested stock options are eligible to continue to vest for the duration of the term of the Transition Agreement Amendment.
The foregoing description is a summary of the Transition Agreement Amendment and is qualified in its entirety by reference to the full text of the Transition Agreement Amendment, a copy of which will be filed as exhibit to the Company's Annual Report on Form 10-Kfor the fiscal year ended December 31, 2025.